Dendrogenix

TLDR

Belgium-based biotech company developing Dendrogenins, small molecule therapies for hearing loss and neurological diseases.

Overview

Dendrogenix is a Belgian biopharmaceutical company founded in 2018 specializing in the development of Dendrogenins, cholesterol derivatives that stimulate cell differentiation in the immune and nervous systems. The company focuses on preclinical and clinical development of these molecules, primarily targeting auditory degeneration and neurological dysfunction with unmet medical needs. Dendrogenix has developed international research partnerships with academic centers including GIGA-Neurosciences at the University of Liège and the University of Tübingen in Germany.